A Phase 1 interventional study of BMS-986141 and Placebo in Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-31.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing aspirin in Thrombosis — 2 open to participants now, 3 under way, none of them phase 3. Aspirin · Thrombosis.
Among the 28 studies testing aspirin in Thrombosis, this one is the 12th largest by enrollment, is one of 4 that started in 2014, is one of 4 in phase 1, and was the 14th registered.
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
Browse Thrombosis studies →2 of the 28 studies testing aspirin in Thrombosis are open now, in 2 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Zealand University Hospital · Sites in Denmark
Ages 18–85
By country, each count listing its studies:
Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 148 is above the median of 83 across 530 interventional studies indexed under Thrombosis.
Median enrollment 106 across the 28 interventional studies. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 28 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
19 studies in Thrombosis by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 19 finished, 7 (37%) have results posted.
Among the 19 studies in Thrombosis by Bristol-Myers Squibb, this one is the 5th largest by enrollment, is one of 2 that started in 2014, is one of 13 in phase 1, and was the 4th registered.
Bristol-Myers Squibb’s Thrombosis studies by the year they started, since 2006.
2 of the studies testing aspirin in Thrombosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04330729Zealand University HospitalThe Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp | 2026-12-31 |
| NCT07613840Massachusetts General HospitalPersonalizing Thromboprophylaxis for Patients With Peripheral Artery Disease | 2027-04-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies testing aspirin in Thrombosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 19 in Thrombosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single and multiple oral doses of BMS-986141 in healthy subjects.
Maximum Age:
Part A SAD 65 years
Part B MAD 75 years
Part C MAD Japanese 75 years
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMS-986141 or Placebo single dose by mouth as specified
Drug: BMS-986141 · Drug: Placebo
BMS-986141 or Placebo single dose by mouth as specified
Drug: BMS-986141 · Drug: Placebo
BMS-986141 or Placebo single dose by mouth as specified
Drug: BMS-986141 · Drug: Placebo
BMS-986141 or Placebo single dose by mouth as specified
Drug: BMS-986141 · Drug: Placebo
BMS-986141 or Placebo single dose by mouth as specified
Drug: BMS-986141 · Drug: Placebo
BMS-986141 or Placebo single dose by mouth as specified
Drug: BMS-986141 · Drug: Placebo
Single dose by mouth as specified
Drug: BMS-986141
Single dose by mouth as specified
Drug: BMS-986141
BMS-986141 or Placebo by mouth as specified
Drug: BMS-986141 · Drug: Placebo
BMS-986141 or Placebo by mouth as specified
Drug: BMS-986141 · Drug: Placebo
BMS-986141 or Placebo by mouth as specified
Drug: BMS-986141 · Drug: Placebo
BMS-986141 or Placebo by mouth as specified
Drug: BMS-986141 · Drug: Placebo
BMS-986141 or Placebo by mouth as specified
Drug: BMS-986141 · Drug: Placebo
BMS-986141 or Placebo by mouth as specified
Drug: BMS-986141 · Drug: Placebo
BMS-986141 and Aspirin by mouth as specified
Drug: BMS-986141 · Drug: Aspirin
BMS-986141 placebo and Aspirin by mouth as specified
Drug: Placebo · Drug: Aspirin
BMS-986141 and Itraconazole by mouth as specified
Drug: BMS-986141 · Drug: Itraconazole
Safety measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations
Serious adverse event (SAE) Adverse event (AE) Electrocardiogram (ECG)
Time frame: Up to 30 days post discontinuation of dosing or last participation in the study
Tolerability measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations
Time frame: Up to 30 days post discontinuation of dosing or last participation in the study
Safety measured by percent of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations
Time frame: Up to 30 days post discontinuation of dosing or last participation in the study
Tolerability measured by percent of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations
Time frame: Up to 30 days post discontinuation of dosing or last participation in the study
Maximum observed plasma concentration (Cmax) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551
Time frame: Up to Day 14
Time of maximum observed plasma concentration (Tmax) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551
Time frame: Up to Day 14
Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986141, BMT-162853, BMT-162856, and BMT-181551
Time frame: Up to Day 14
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986141, BMT-162853, BMT-162856, and BMT-181551
Time frame: Up to Day 14
Concentration at 24 hours (C24) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551
Time frame: Up to Day 14
Half-life (T-HALF) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551
Time frame: Up to Day 14
Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986141, BMT-162853, BMT-162856, and BMT-181551
Time frame: Up to Day 14
AUC accumulation index (AI_AUC) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551; ratio of AUC(TAU) at steady-state to AUC(TAU) after the first dose
Time frame: Up to Day 14
Effective elimination half-life that explains the degree of AUC accumulation observed (T-HALFeff_AUC) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551
Time frame: Up to Day 14
MR_Cmax of BMT-162853, BMT-162856, and BMT-181551
Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax)
Time frame: Up to Day 14
MR_AUC(INF) of BMT-162853, BMT-162856, and BMT-181551
Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight \[MR_AUC(INF)\]
Time frame: Up to Day 14
MR_AUC(0-T) of BMT-162853, BMT-162856, and BMT-181551
Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight \[MR_AUC(0-T)\]
Time frame: Up to Day 14
MR_AUC(TAU) of BMT-162853, BMT-162856, and BMT-181551
Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight \[MR_AUC(TAU)\]
Time frame: Up to Day 14
Safety of multiple doses of BMS-986141 and aspirin in healthy subjects
Safety measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations.
Time frame: Up to 30 days post discontinuation of dosing or last participation in the study
Tolerability of multiple doses of BMS-986141 and aspirin in healthy subjects
Tolerability measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations
Time frame: Up to 30 days post discontinuation of dosing or last participation in the study
Safety of BMS-986141 and itraconazole in healthy subjects
Safety measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations
Time frame: Up to 30 days post discontinuation of dosing or last participation in the study
Tolerability of BMS-986141 and itraconazole in healthy subjects
Tolerability measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations
Time frame: Up to 30 days post discontinuation of dosing or last participation in the study
The record gives a start of Sep 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: BMS-986141 · Aspirin